Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

doi:10.3748/wjg.v26.i2.199

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9046)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-4) series.

Item

Count

PDF

717

WORD

238

HTML

5439

Figures (1-10)

256

Tables (1-4)

244

Sum=6894

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

834

Download

1318

Sum=2152

Jan 14, 2020 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jan 14, 2020; 26(2): 199-218
Published online Jan 14, 2020. doi: 10.3748/wjg.v26.i2.199

Full Size Figure Download Figure

Figure 2 Gray’s test showed that the cumulative survival was significantly higher in the rifaximin group than in the control group. ^aP < 0.05 vs control group.

Citation: Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218
URL: https://www.wjgnet.com/1007-9327/full/v26/i2/199.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i2.199